Together with colleagues from the MRC-Mitochondrial Biology Unit (University of Cambridge), Tom Schirris, theme Metabolic disorders, published a research article entitled “Characterization of drug-induced human mitochondrial ADP/ATP carrier inhibition” in Theranostics.
An increasing number of commonly prescribed drugs are known to interfere with mitochondrial function, causing cellular toxicity, but the underlying mechanisms are largely unknown. Although often not considered, mitochondrial transport proteins form a significant class of potential mitochondrial off-targets. So far, most drug interactions have been reported for the mitochondrial ADP/ATP carrier (AAC), which exchanges cytosolic ADP for mitochondrial ATP. However, these claims have never been validated and a simple, direct model system to evaluate and compare drug-induced AAC inhibition is lacking. Here, we provide a characterization of the human AAC1 and demonstrate its relevance to study drug-induced inhibition. Our work also paves the way to study many other mitochondrial transport proteins that could be relevant drug off-targets. Consequently, these analyses will eventually provide insights in the role of mitochondrial transport proteins in drug-induced mitochondrial dysfunction and will thereby contribute to the development of drugs with an enhanced safety profile.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items

Patients who are obese or overweight are at risk for a more severe course of COVID-19
19 April 2021International study shows risk of mortality does not increase
read more
New way of diagnostics detects 'undetectable' genetic defects
15 April 2021Research provides guidance for global application
read more
Vici grant for Michiel Vermeulen Reading the epitranscriptome
15 April 2021Michiel Vermeulen, theme Cancer development and immune defense, has been awarded a Vici grant from the Netherlands Organisation for Scientific Research (NWO), one of the largest personal scientific awards in the Netherlands.
read more
2.5 million Euros for cancer research into ovarian cancer and immunotherapy
15 April 2021The Radboudumc receives 2.5 million Euros from the Dutch Cancer Society (KWF) for three studies to ensure oncological progress during COVID-19 period.
read more
COVID-19 regulations for nursing homes have varying effects
14 April 2021On May 11th 2020, the Dutch Government allowed 26 nursing homes to welcome one visitor per resident, after two months of lockdown. An in-depth Radboudumc study monitored the feasibility of the regulations and the impact on the well-being of residents, their visitors, and healthcare staff.
read more